We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

72 hedge funds and large institutions have $128M invested in ANI Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less funds holding

Funds holding: 81 → 72 (-9)

18% less capital invested

Capital invested by funds: $156M → $128M (-$27.8M)

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

Holders
72
Holders Change
-9
Holders Change %
-11.11%
% of All Funds
2.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
32
Reduced
20
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CCM
Consonance Capital Management
New York
+$5.83M
2
HVC
Healthcare Value Capital
New Jersey
+$4.53M
3
Wells Fargo
Wells Fargo
California
+$3.06M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$2.83M
5
TI
Turner Investments
Pennsylvania
+$2.27M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$7.79M
2
LOAMU
Lombard Odier Asset Management (USA)
New York
-$5.17M
3
EI
EAM Investors
California
-$3.03M
4
Morgan Stanley
Morgan Stanley
New York
-$3.01M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$144K +$6.53K +218 +4%
BA
52
BlackRock Advisors
Delaware
$129K -$13.8K -459 -9%
AIG
53
American International Group
New York
$127K -$120 -4 -0.1%
Barclays
54
Barclays
United Kingdom
$115K +$108K +3,588 +680%
Allianz Asset Management
55
Allianz Asset Management
Germany
$90K – – –
AllianceBernstein
56
AllianceBernstein
Tennessee
$79K – – –
U
57
UBS
Switzerland
$72K +$57.6K +1,923 +312%
Bank of America
58
Bank of America
North Carolina
$34K -$129K -4,300 -78%
WA
59
WFG Advisors
Texas
$28K -$42K -1,400 -58%
GSC
60
Ground Swell Capital
South Carolina
$24K +$25K +833 New
SFU
61
Stonehage Fleming (UK)
United Kingdom
$12K -$13.1K -436 -51%
Citigroup
62
Citigroup
New York
$7K +$4.88K +163 +151%
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$5K -$30K -1,000 -84%
BlackRock
64
BlackRock
New York
$5K – – –
MFBTD
65
MB Financial Bank - Trust Department
Illinois
$4K +$1.77K +59 +100%
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$3.2K +$3.39K +113 New
Canada Life
67
Canada Life
Manitoba, Canada
$2K – – –
Deutsche Bank
68
Deutsche Bank
Germany
$1K +$989 +33 +97%
WEC
69
Winslow Evans & Crocker
Massachusetts
$370 +$30 +1 +8%
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$120 -$9.14K -305 -7%
LOAMU
71
Lombard Odier Asset Management (USA)
New York
– -$5.17M -150,000 Closed
EI
72
EAM Investors
California
– -$3.03M -87,883 Closed
GC
73
Guggenheim Capital
Illinois
– -$2.25M -65,222 Closed
Goldman Sachs
74
Goldman Sachs
New York
– -$1.04M -30,201 Closed
Susquehanna International Group
75
Susquehanna International Group
Pennsylvania
– -$628K -18,244 Closed
1 2
3
4

ANIP Hedge Fund Activity: Q3 2014 in Review

72 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2014, worth a combined $128M — down 18% from $156M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ANIP and 6 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 32 added.

The largest buyer was Consonance Capital Management, adding an estimated $5.83M. The largest seller was Millennium Management, cutting an estimated $7.79M.

  • 72 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2014, down from 81 in Q2 2014.
  • Funds reported $128M of ANI Pharmaceuticals stock for Q3 2014, down 18% quarter-over-quarter.
  • 6 funds opened new ANI Pharmaceuticals positions in Q3 2014 and 15 closed out, a net change of -9 holders.
  • The largest ANI Pharmaceuticals buyer in Q3 2014 was Consonance Capital Management, an estimated $5.83M added.
  • The largest ANI Pharmaceuticals seller in Q3 2014 was Millennium Management, an estimated $7.79M sold.

Based on aggregated 13F filings for Q3 2014.